Sucralfate in the treatment of reflux esophagitis in children. Preliminary results.
In order to evaluate the use of sucralfate in the treatment of children with reflux esophagitis, we studied 66 children aged from 4 months to 12 years (mean 5.9 years, SD 3.5) diagnosed to have gastroesophageal reflux by means of esophageal isotopic examination and radiology. An endoscopic examination was carried out in all cases. None of the patients suffered from kidney disease or had taken antacids, cimetidine, sucralfate or antirheumatic drugs in the two weeks prior to the study. Patients were divided into three groups matched according to age, grade of esophagitis, sex, nutritional state and semiology and treated with sucralfate in tablets, cimetidine, or sucralfate in suspension; no dietetic or postural measures were used. On days 14, 28, 42 and 56, clinical control was carried out and endoscopy was done on day 28, this being repeated on day 56 if the course was not satisfactory. From the statistical analysis of the results we deduce that there are no differences between the three groups. Therefore sucralfate appears to be a useful drug for the treatment of children with esophagitis due to GER.
Argüelles-Martín
F
F
Department of Pediatrics, University Hospital Virgen de la Macarena, Seville, Spain.
González-Fernández
F
F
Gentles
M G
MG
Navarro-Merino
M
M
D002648:Child; D002675:Child, Preschool; D002927:Cimetidine / Q000627:therapeutic use*; D004942:Esophagitis, Peptic / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D013392:Sucralfate / Q000008:administration & dosage / Q000627:therapeutic use*; D013535:Suspensions; D013607:Tablets
D013535:Suspensions; D013607:Tablets; D013392:Sucralfate; D002927:Cimetidine